The oesophageal adenocarcinoma tumour immune microenvironment dictates outcomes with different modalities of neoadjuvant therapy - results from the AGITG DOCTOR trial and the cancer evolution biobank.

Front Immunol · 2023 · PMC10642165 · PMID 37965317

Europe PMC DOI

hedged sentence

0.0620

closest p · 1.2× alpha

0.0620

boldest claim

The sentences

showed a trendp = 0.062so close (0.05 < p ≤ 0.1)

Despite this, nCT treated patients showed a trend towards higher CD8 + cells post-therapy (p = 0.062), with less exhausted CD8 + T cells compared to CD8 + T cells and TILs post therapy (p = 0.013, and p = 0.0077, respectively; Figure 6B ). nCRT patients had an increased macrophage (p = 0.0074) and dendritic cell signature (p = 0.023), as well as a decreased T cell to TIL ratio post treatment (p = 0.014; Figure 6B ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.